Evidence map›Paper›PMID 41145285›Full record

ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2025

[Bendamustine combined with anti-CD20 monoclonal antibody in the first-line treatment of older patients with indolent B-cell non-Hodgkin lymphoma: a multicenter retrospective study].

S C Qin, Y Miao, Z L Zhang, J Zhang, Y Y Shi, Y Q Miao, W Y Gu, W C Zheng, Z X Jia, G Q Lin and 10 more

Abstract readMulticenter StudyEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

S C QinDepartment of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China.
Y MiaoDepartment of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China.
Z L ZhangDepartment of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China.
J ZhangDepartment of Oncology, Affiliated Hospital of Nantong University, Nantong 226001, China.
Y Y ShiDepartment of Hematology, Huai'an First People's Hospital, Huai'an 223000, China.
Y Q MiaoDepartment of Hematology, the First People's Hospital of Yancheng, Yancheng 224001, China.
W Y GuDepartment of Hematology, the First People's Hospital of Changzhou, Changzhou 213003, China.
W C ZhengDepartment of Hematology, the Second Affiliated Hospital of Soochow University, Suzhou 215000, China.
Z X JiaDepartment of Hematology, Affiliated Changzhou Second Hospital of Nanjing Medical University, Changzhou 213003, China.
G Q LinDepartment of Hematology, Affiliated Huai'an Hospital of Xuzhou Medical University, Huai'an Second People's Hospital, Huai'an 223002, China.
H W NiDepartment of Hematology, Jiangsu Province Hospital of Chinese Medicine, Nanjing 210029, China.
X H XuDepartment of Hematology and Lymphoma, Nantong Tumor Hospital, Nantong 226361, China.
M XuDepartment of Hematology, the General Public Hospital of Zhangjiagang, Zhangjiagang 215600, China.
X Y XieDepartment of Hematology, Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou 225009, China.
L WangDepartment of Hematology, Nantong First People's Hospital, Nantong 226014, China.
Y ZhuangDepartment of Hematology, Wuxi People's Hospital, Wuxi 214023, China.
W ZhangDepartment of Hematology, the Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing 211100, China.
P LiuDepartment of Hematology, Wuxi No.2 People's Hospital, Wuxi 214000, China.
J Y LiDepartment of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China.
W Y ShiDepartment of Oncology, Affiliated Hospital of Nantong University, Nantong 226001, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBendamustine HydrochlorideLymphoma, B-CellLymphoma, Non-HodgkinAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntigens, CD20FemaleHumansMaleMiddle AgedRetrospective StudiesRituximabTreatment OutcomeAntibodies, Monoclonal, HumanizedAntigens, CD20Bendamustine HydrochlorideobinutuzumabRituximabB-cell indolent lymphomaBendamustine hydrochlorideElderlyFirst-line therapy

Identifiers

PMID41145285
PMCPMC12580820

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.